Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4026-4034

  Irwin, Scott M ^a   Gruppo, Veronica ^a   Brooks, Elizabeth ^a   Gilliland, Janet ^a   Scherman, Michael ^a   Reichlen, Matthew J ^b   Leistikow, Rachel ^b   Kramnik, Igor ^c   Nuermberger, Eric L ^d   Voskuil, Martin I ^b   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; GAMMA INTERFERON; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CELL AGGREGATION; CLINICAL EFFECTIVENESS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EPITHELIOID MACROPHAGE; FEMALE; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; LUNG GRANULOMA; LUNG NECROSIS; LYMPHOCYTE; MACROPHAGE; MONOTHERAPY; MOUSE; MOUSE MODEL; NECROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; C3H MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; GRANULOMA; KNOCKOUT MOUSE; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CLOFAZIMINE; DISEASE MODELS, ANIMAL; FEMALE; GRANULOMA; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, KNOCKOUT; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NECROSIS; TUBERCULOSIS;

EID: 84903188913     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02565-14     Document Type: Article

References (52)

1. Glaziou P, Falzon D, Floyd K, Raviglione M. 2013. Global epidemiology of tuberculosis. Semin. Respir. Crit. Care Med. 34:3-16. http://dx.doi.org/10.1055/ s-0032-1333467.
2. Dye C, Glaziou P, Floyd K, Raviglione M. 2013. Prospects for tuberculosis elimination. Annu. Rev. Public Health 34:271-286. http://dx.doi.org/10.1146/ annurev-publhealth-031912-114431.
3. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, Twomey D, Winder F. 1957. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179:1013-1015. http://dx.doi.org/10.1038/ 1791013a0.
4. Barry VC, Buggle K, Byrne J, Conalty ML, Winder F. 1960. Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir. J. Med. Sci. 416:345-352.
5. Vischer WA. 1969. The experimental properties of G 30 320 (B 663) - a new anti-leprotic agent. Lepr. Rev. 40:107-110.
6. Schmidt L, Hoffman R, Jolly P. 1955. Induced pulmonary tuberculosis in the rhesus monkey: its usefulness in evaluating chemotherapeutic agents. Proceedings of the 14th V.A.-A.V. Conference on Tuberculosis, p 226-231. Veterans Administration, Atlanta, GA.
7. Jagannath C, Reddy MV, Kailasam S, O'Sullivan JF, Gangadharam PR. 1995. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am. J. Respir. Crit. Care Med. 151:1083-1086. http://dx.doi.org/10.1164/ajrccm/151.4.1083.
8. Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D, Huang H, Upton AM, Ma Z. 2011. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob. Agents Chemother. 55:5185-5193. http://dx.doi.org/10.1128/AAC.00699-11.
9. Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong N, Lv Y, Li C, Cooper CB, Upton AM, Yin D, Ma Z, Huang H. 2012. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J. Med. Chem. 55:8409-8417. http://dx.doi.org/10.1021/jm300828h.
10. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
11. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trebucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am. J. Respir. Crit. Care Med. 188:608-612. http://dx.doi.org/10.1164/rccm.201304-0753OC.
12. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
13. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56:3114-3120. http://dx.doi.org/10. 1128/AAC.00384-12.
14. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J. 2012. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205(Suppl 2):S241-S249.
15. Banerjee DK, Ellard GA, Gammon PT, Waters MF. 1974. Some observations on the pharmacology of clofazimine (B663). Am. J. Trop. Med. Hyg. 23:1110-1115.
16. McDougall AC. 1974. Electron microscope studies of the antileprosy drug B663 (clofazimine; Lamprenel). Int. J. Lepr. Other Mycobact. Dis. 42:1-12.
17. McDougall AC, Horsfall WR, Hede JE, Chaplin AJ. 1980. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. Br. J. Dermatol. 102:227-230. http://dx.doi.org/10.1111/j.1365-2133.1980.tb05697.x. (Pubitemid 10148345)
18. Prinsloo Y, van Rensburg CE, van der Walt R, Anderson R. 1995. Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669. Inflamm. Res. 44:379-385. http://dx.doi.org/10.1007/BF01797865.
19. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, Cho SN, Via LE, Barry CE, III. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122-128. http://dx.doi.org/10.1378/chest.09-0903.
20. Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, Basaraba RJ, Lenaerts AJ. 2011. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6:e17550. http://dx.doi.org/10.1371/journal.pone. 0017550.
21. Kramnik I, Demant P, Bloom BB. 1998. Susceptibility to tuberculosis as a complex genetic trait: analysis using recombinant congenic strains of mice. Novartis Found. Symp. 217:120-131; discussion, 132-137.
22. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, Kobzik L, Higgins DE, Daly MJ, Bloom BR, Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767-772. http://dx.doi.org/10.1038/nature03419. (Pubitemid 44739520)
23. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217- 12.
24. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J. Infect. Dis. 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
25. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301. http://dx.doi.org/10.1128/AAC.49.6.2294-2301.2005. (Pubitemid 40734457)
26. Orme IM. 1996. Immune responses in animal models. Curr. Top. Microbiol. Immunol. 215:181-196. (Pubitemid 26270596)
27. Kim TH, Kubica GP. 1972. Long-term preservation and storage of mycobacteria. Appl. Microbiol. 24:311-317.
28. Leistikow RL, Morton RA, Bartek IL, Frimpong I, Wagner K, Voskuil MI. 2010. The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J. Bacteriol. 192:1662-1670. http://dx.doi.org/10.1128/JB.00926-09.
29. Rhoades ER, Frank AA, Orme IM. 1997. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung Dis. 78:57-66. http://dx.doi.org/10.1016/S0962- 8479(97)90016-2. (Pubitemid 28019788)
30. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069. (Pubitemid 26165667)
31. Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am. J. Pathol. 174:2190-2201. http://dx.doi.org/10.2353/ajpath.2009.081075.
32. Krajewska MM, Anderson R, O'Sullivan JF. 1993. Effects of clofazimine analogues and tumor necrosis factor-alpha individually and in combination on human polymorphonuclear leukocyte functions in vitro. Int. J. Immunopharmacol. 15:99-111. http://dx.doi.org/10.1016/0192-0561(93)90086-E. (Pubitemid 23096235)
33. Anderson R, Lukey P, Van Rensburg C, Dippenaar U. 1986. Clofazimine-mediated regulation of human polymorphonuclear leukocyte migration by pro-oxidative inactivation of both leukoattractants and cellular migratory responsiveness. Int. J. Immunopharmacol. 8:605-620. http://dx.doi.org/10.1016/ 0192-0561(86)90033-0. (Pubitemid 16027107)
34. van Rensburg CE, Gatner EM, Imkamp FM, Anderson R. 1982. Effects of clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob. Agents Chemother. 21:693-697. http://dx.doi.org/10.1128/AAC.21.5. 693. (Pubitemid 12006512)
35. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, Dang Y, Zhang J, Jiang H, Penner R, Liu JO. 2008. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 3:e4009. http://dx.doi.org/10.1371/journal.pone.0004009.
36. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254. http://dx.doi.org/10.1084/jem.178.6.2249. (Pubitemid 23344886)
37. Saunders BM, Cooper AM. 2000. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell Biol. 78:334-341. http://dx.doi.org/10.1046/j.1440-1711.2000.00933.x. (Pubitemid 30655559)
38. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286:10276-10287. http://dx.doi.org/10.1074/jbc.M110.200501.
39. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involvement of reactive oxygen species. Science 339:1210-1213. http://dx.doi.org/10.1126/science.1232751.
40. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339:1213-1216. http://dx.doi.org/10.1126/science.1232688.
41. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1380-1385. http://dx.doi.org/10.1128/AAC.00055-06. (Pubitemid 46586820)
42. Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P. 2012. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int. J. Tuberc. Lung Dis. 16:1119-1125. http://dx.doi.org/10.5588/ijtld.11.0752.
43. Barry V. 1964. The development of chemotherapeutic agent for tuberculosis, p 46-64. In Barry V (ed), Chemotherapy of tuberculosis. Butterworth & Co., London, England.
44. Barry VC, Conalty ML. 1965. The antimycobacterial activity of B 663. Lepr. Rev. 36:3-7.
45. Aplin RT, McDougall AC. 1975. Identification of crystals of the riminophenazine compound B663 (Lamprene: clofazimine) in mouse spleen macrophages by thin layer chromatography and mass spectrum analysis. Experientia 31:468-469. http://dx.doi.org/10.1007/BF02026384.
46. Baik J, Rosania GR. 2012. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One 7:e47494. http://dx.doi.org/10.1371/journal.pone.0047494.
47. Sandler ED, Ng VL, Hadley WK. 1992. Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 116:541-543.
48. Reddy VM, O'Sullivan JF, Gangadharam PR. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623. http://dx.doi.org/10.1093/jac/43.5.615. (Pubitemid 29231686)
49. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE, III, Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem. 83:2112-2118. http://dx.doi.org/10.1021/ac1029049.
50. Global Alliance for TB Drug Development. 2013. Evaluation of early bactericidal activity in pulmonary tuberculosis with clofazimine, TMC207, PA-824, pyrazinamide (NC-003); NCT01691534. http://clinicaltrials.gov/ct2/show/ NCT01691534.
51. Donald PR, Diacon AH. 2008. The early bactericidal activity of antituberculosis drugs: a literature review. Tuberculosis (Edinb.) 88(Suppl 1):S75-S83. http://dx.doi.org/10.1016/S1472-9792(08)70038-6.
52. Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W. 1987. Pharmacokinetics of clofazimine in healthy volunteers. Int. J. Lepr. Other Mycobact. Dis. 55:9-15. (Pubitemid 17071023)